From 2008 to 2015, there was a significant shift in site of care from physician offices to more expensive 340B hospital outpatient settings for certain classes of physician-administered medicines, according to a new analysis by the Berkeley Research Group (BRG) that was commissioned by the Pharmaceutical Research and Manufacturers of America (PhRMA). For Medicare beneficiaries and patients with private health insurance whose insurance does not fully cover the cost of their treatment, this shift in site of care often results in increased costs for their share of the bill. This undermines the purpose of the 340B program, which is to help safety-net facilities access discounted medicines for the vulnerable and uninsured.

Continue reading on PR Newswire.